Efendic S, Bystedt T, Ostenson C G
Kliniken för endokrinologi och diabetologi, Karolinska sjukhuset, Stockholm.
Lakartidningen. 1999 Feb 24;96(8):888-92.
The pharmacological arsenal available today for the treatment of type II diabetes is often insufficient to allow optimal control of the disease. Each agent corrects only one or a few of the multiple defects that characterise type II diabetes. Currently, new drugs are under development that target several of the clinical abnormalities. These agents include the gastrointestinal peptides, glucagon-like polypeptide-1 (GLP-1) and amylin, and their analogues. New rapid- and long-acting insulin analogues will also constitute interesting treatment alternatives.
